Abiopharma

🔍 Carrai Phillip D (Executive)

Company: KRATOS DEFENSE & SECURITY SOLUTIONS, INC. (KTOS)

Report Date: 2026-04-15

Detailed Transactions and Holdings:

• Sold 1,645 shares of Common Stock at $74.0769 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 232,753.00 | transaction_form_type: 4 | Footnotes: F1, F2, F5
• Sold 3,955 shares of Common Stock at $74.7991 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 228,798.00 | transaction_form_type: 4 | Footnotes: F1, F3, F5
• Sold 900 shares of Common Stock at $75.5619 per share (Direct)
  Date: 2026-04-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 227,898.00 | transaction_form_type: 4 | Footnotes: F1, F4, F5
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-15 | Code: H | nature_of_ownership: by trust | shares_owned_after: 46,644.00

Footnotes:

• F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person on August 26, 2025.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.47 to $74.45 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.47 to $75.46 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.48 to $75.68 inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
• F5: Includes 1,232 shares purchased through Issuer's Employee Stock Purchase Plan and approximately 4,351 shares held through Issuer's 401(k) Plan.